

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI328141

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	SECURITY INTEREST	
CONVEYING PARTY DATA		
	Name	Execution Date
	RULES-BASED MEDICINE INC.	06/27/2024
RECEIVING PARTY DATA		
Company Name:	U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT	
Street Address:	Global Corporate Trust Services EP-MN-WS3C	
Internal Address:	60 Livingston Avenue	
City:	St. Paul	
State/Country:	MINNESOTA	
Postal Code:	55107	
PROPERTY NUMBERS Total: 10		
Property Type	Number	
Patent Number:	10954508	
Patent Number:	8361730	
Application Number:	17163170	
Application Number:	18592456	
Application Number:	18592473	
Application Number:	18592484	
Application Number:	18592499	
Application Number:	17195548	
PCT Number:	US2236422	
PCT Number:	US2362876	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(617)854-2079	
Email:	jonathan.bradford@ropesgray.com	
Correspondent Name:	Jonathan Bradford	
Address Line 1:	Prudential Tower	
Address Line 2:	800 BOYLSTON STREET	

Address Line 4: Boston, MASSACHUSETTS 02199-3600	
ATTORNEY DOCKET NUMBER:	116153-0008
NAME OF SUBMITTER:	Jonathan Bradford
SIGNATURE:	Jonathan Bradford
DATE SIGNED:	06/27/2024
Total Attachments: 6 source=IQVIA - Patent Security Agreement (Rules-Based Medicine) (November 2023) - USB (A_B) - Executed Jun-27-24#page1.tiff source=IQVIA - Patent Security Agreement (Rules-Based Medicine) (November 2023) - USB (A_B) - Executed Jun-27-24#page5.tiff source=IQVIA - Patent Security Agreement (Rules-Based Medicine) (November 2023) - USB (A_B) - Executed Jun-27-24#page4.tiff source=IQVIA - Patent Security Agreement (Rules-Based Medicine) (November 2023) - USB (A_B) - Executed Jun-27-24#page2.tiff source=IQVIA - Patent Security Agreement (Rules-Based Medicine) (November 2023) - USB (A_B) - Executed Jun-27-24#page3.tiff source=IQVIA - Patent Security Agreement (Rules-Based Medicine) (November 2023) - USB (A_B) - Executed Jun-27-24#page6.tiff	

PATENT SECURITY AGREEMENT

Patent Security Agreement, dated as of June 27, 2024, by and among Rules-Based Medicine Inc., a Delaware corporation (the “Pledgor”), in favor of U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, in its capacity as collateral agent pursuant to the Indenture (in such capacity, the “Collateral Agent”).

WITNESSETH:

WHEREAS, the Pledgor is party to a Pledge and Security Agreement, dated as of November 28, 2023 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”), in favor of the Collateral Agent pursuant to which the Pledgor is required to execute and deliver this Patent Security Agreement;

NOW, THEREFORE, in consideration of the premises and to induce the Collateral Agent, for the benefit of the Secured Parties, to enter into the Indenture, the Pledgor hereby agrees with the Collateral Agent as follows:

SECTION 1. Defined Terms. Unless otherwise defined herein, terms defined in the Security Agreement and used herein have the meaning given to them in the Security Agreement.

SECTION 2. Grant of Security Interest in Patent Collateral. The Pledgor hereby pledges and grants to the Collateral Agent for the benefit of the Secured Parties a lien on and security interest in and to all of its right, title and interest in, to and under all Patents of such Pledgor listed on Schedule I attached hereto.

SECTION 3. Security Agreement. This Patent Security Agreement has been executed and delivered by the Pledgor for the purpose of recording the grant of security interest herein with the United States Patent and Trademark Office. The security interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interest granted to the Collateral Agent pursuant to the Security Agreement and the Pledgor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the security interest in the Patents made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event that any provision of this Patent Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall control.

SECTION 4. Termination. Upon termination of the Security Agreement in accordance with Section 11 thereof, the Collateral Agent shall execute, acknowledge, and deliver to the Pledgor an instrument in writing in recordable form releasing the collateral pledge, grant, assignment, lien and security interest in the Patents under this Patent Security Agreement.

SECTION 5. Counterparts. This Patent Security Agreement may be executed in any number of counterparts, all of which shall constitute one and the same instrument, and any party hereto may execute this Patent Security Agreement by signing and delivering one or more counterparts.

SECTION 6. Governing Law. This Patent Security Agreement and the transactions contemplated hereby, and all disputes between the parties under or relating to this Patent Security


Agreement or the facts or circumstances leading to its execution, whether in contract, tort or otherwise, shall be construed in accordance with and governed by the laws (including statutes of limitation) of the State of New York.

[signature page follows]

IN WITNESS WHEREOF, the Pledgor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Very truly yours,

RULES-BASED MEDICINE INC.

By: 

Name: Kerri Joseph


Title: Vice President & Treasurer

[Patent Security Agreement]

PATENT
REEL: 067859 FRAME: 0405

Accepted and Agreed:

U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION,
as Collateral Agent

By: _____
Name: Brandon Bonfig
Title: Vice President

SCHEDULE I
to
PATENT SECURITY AGREEMENT

Patents:

Owner	Patent Title	Appl. No. Filing Date	Publication No. Publication Date
RULES-BASED MEDICINE INC.	ANTIBODY LIBRARIES WITH MAXIMIZED ANTIBODY DEVELOPABILITY CHARACTERISTICS	16/505,358 July 8, 2019	10,954,508 March 23, 2021
Myriad Genetics, Inc.	ILCS BASED PATTERN RECOGNITION OF SEPSIS	11/960,413 December 19, 2007	8,361,730 January 29, 2013

Patent Applications:

Owner	Patent Title	Appl. No. Filing Date	Publication No. Publication Date
RULES-BASED MEDICINE INC.	ANTIBODY LIBRARIES WITH MAXIMIZED ANTIBODY DEVELOPABILITY CHARACTERISTICS	17/163,170 (2021/0171936)	--
RULES-BASED MEDICINE INC.	ANTIBODY AFFINITY MATURATION USING NATURAL LIABILITY-FREE CDRS	PCT/US2022/036422 (WO2023283383A1)	--
RULES-BASED MEDICINE INC.	SINGLE DOMAIN ANTIBODY LIBRARIES WITH MAXIMIZED ANTIBODY DEVELOPABILITY CHARACTERISTICS	PCT/US2023/062876 (WO2023159221A1)	--
RULES-BASED MEDICINE INC.	ANTIBODY LIBRARIES WITH MAXIMIZED ANTIBODY DEVELOPABILITY CHARACTERISTICS	18/592,456	--
RULES-BASED MEDICINE INC.	ANTIBODY LIBRARIES WITH MAXIMIZED ANTIBODY DEVELOPABILITY	18/592,473	--

Owner	Patent Title	Appl. No. Filing Date	Publication No. Publication Date
	CHARACTERISTICS		
RULES-BASED MEDICINE INC.	ANTIBODY LIBRARIES WITH MAXIMIZED ANTIBODY DEVELOPABILITY CHARACTERISTICS	18/592,484	--
RULES-BASED MEDICINE INC.	ANTIBODY LIBRARIES WITH MAXIMIZED ANTIBODY DEVELOPABILITY CHARACTERISTICS	18/592,499	--
RULES-BASED MEDICINE INC.	METHODS AND DEVICES FOR DETECTING DIABETIC NEPHROPATHY AND ASSOCIATED DISORDERS	17/195,548	--